Navigation Links
Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)
Date:5/19/2009

of IPF-related deaths during treatment was also lower among patients treated with pirfenidone. IPF-related deaths occurred during the treatment period in 4.1% of patients in the pirfenidone group and 8.1% of patients in the placebo group in CAPACITY 1. IPF-related deaths occurred during the treatment period in 2.9% of pirfenidone group and 6.3% of patients in the placebo group in CAPACITY 2.

Treatment Discontinuation due to Adverse Events

Pirfenidone was safe and generally well tolerated. Relatively few adverse events resulted in treatment discontinuations. The percentage of patients in the 2403 mg pirfenidone and placebo groups across both CAPACITY studies who discontinued treatment (pirfenidone/placebo) due to various adverse events were as follows: IPF (2.9/2.6); rash (1.4/0); nausea (1.4/0); bladder cancer (0.9/0); photosensitivity reaction (0.9/0.3); respiratory failure (0.9/0.3) and weight decrease (0.6/0).

Laboratory Tests

A total of 30 laboratory tests were regularly performed in CAPACITY. The incidence of grade 3/4 laboratory abnormalities was similar between treatment groups in both studies. In six of the tests, Grade 3/4 abnormalities were noted slightly more frequently in patients treated with pirfenidone (phosphate elevation, hyponatremia, lymphopenia, ALT elevation, AST elevation and cholesterol elevation). Of these laboratory abnormalities in pirfenidone patients, all but one case each of hyponatremia and lymphopenia were Grade 3. In four of the laboratory tests, Grade 3/4 abnormalities were noted slightly more frequently in patients treated with placebo (urate elevation, hyperkalemia, amylase elevation and creatine kinase elevation). Both the incidence of grade 3/4 lab abnormalities and the differences observed between treatment groups on all tests were small.

Regarding the overall safety results, Dr. du Bois commented, "The safety and tolerabilit
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting
4. TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
5. Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clinical Trial
6. AlphaVax Announces Promising Results in Melanoma Studies
7. Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
8. BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results
9. Bionovo Announces First Quarter 2009 Highlights and Financial Results
10. Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status
11. ADVENTRX Announces Results From ANX-514 Bioequivalence Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 2015 RadiologyAuction will have their first auction starting ... demonstrations at the end of the auction on May ... and Fuji Cr,s, Agfa and Sony, printers and GE ... Various imaging equipment will be available at later auctions ... years of buying and selling imaging equipment, the brokers ...
(Date:5/4/2015)... , May 4, 2015 PharmaEngine, ... Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) with ... BAX ) jointly announced that Baxter has submitted ... Medicines Agency (EMA) for MM-398 (irinotecan liposome injection), ... adenocarcinoma of the pancreas who have been previously ...
(Date:5/4/2015)... May 4, 2015  Makindus, Inc. a specialty pharmaceutical ... European Medicines Agency (EMA) has granted orphan drug designation ... Stargardt,s Disease. "We are extremely pleased to ... Stargardt,s disease in place for Europe ... the United States for which ...
Breaking Medicine Technology:RadiologyAuction Announces Event Starting On May 5th 2PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 2PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 3European Medicines Agency (EMA) Grants Orphan Designation for Makindus' MI-100 for Stargardt's Disease 2
... GRASS VALLEY, Calif., Jan. 18, 2011 Eigen, a ... announced the completion of the company,s restructuring plan designed ... billion urology medical device marketplace. The company ... is now positioned with a unified management team and ...
... 2011 Vasomedical, Inc. ("Vasomedical") (OTC Bulletin Board: ... today announced financial results of the three months ended ... the noninvasive treatment of cardiovascular diseases. In addition, the ... VasoHealthcare , commenced operations on July 1, 2010 under ...
Cached Medicine Technology:Vasomedical Reports Financial Results for the Quarter Ended November 30, 2010 2Vasomedical Reports Financial Results for the Quarter Ended November 30, 2010 3Vasomedical Reports Financial Results for the Quarter Ended November 30, 2010 4
(Date:5/5/2015)... (PRWEB) May 05, 2015 The ... for assessing and treating children with feeding and ... the course of 20 years through the clinical ... Kay Toomey , in conjunction with colleagues from ... dieticians, and speech pathologists. Education Resources Inc. is ...
(Date:5/5/2015)... NJ (PRWEB) May 05, 2015 Texting has ... is no surprise that some physicians text as a way ... we urge providers who are doing so to assure medical ... does not come without risk! When providers transmit protected ... mobile devices, they run the risk of violating the Health ...
(Date:5/5/2015)... Curly Hair Solutions™ is delighted to introduce the ... Mist. The collection has every curl type covered, ... loose to medium body curls is exposure to the ocean ... fancying the ocean breeze needn’t leave their bathroom. , ... Mist produces the same invigorating freshness one gets when exposed ...
(Date:5/5/2015)... MA (PRWEB) May 05, 2015 Lauren ... goods retailer City Sports , was named one ... and active lifestyle industry by the SportsOneSource ... , Ms. Blanda, 33, is one of 40 executives ... Sporting Goods Business magazine) recognized for exceptional achievement in ...
(Date:5/4/2015)... Parlin dentist, Dr Mariana Blagoev is extending her ... to participate and win a laptop. , Dr. Blagoev created ... good deeds and share them on her Facebook page. By ... teach them to be kind and compassionate when they mature ... years of age and under. Youths are urged to submit ...
Breaking Medicine News(10 mins):Health News:Commission on Dietetic Registration Approves Two Pediatric Feeding Courses Offered by Education Resources Inc. 2Health News:HIPAA Compliant Texting Service from MedXcom now available for Policyholders 2Health News:Curly Hair Solutions Introduces New Revolutionary Product: Curl Keeper Beach Mist 2Health News:Sporting Goods Trade Group Names City Sports’ Lauren Blanda to Its Annual “40 Under 40” List 2Health News:Sporting Goods Trade Group Names City Sports’ Lauren Blanda to Its Annual “40 Under 40” List 3Health News:10 More Days To Enter Good Deed Contest 2
... a connection with obesity risks as they grow up, more so, in ... team of researchers led by Sarah E. Anderson, M.S., from Tufts University ... and 417 men - who underwent assessment four times between 1983 and ... during the beginning of the study, and were in the age group ...
... deteriorate as they progress through puberty, reveals a new ... levels of insulin, however, remain unchanged in their Caucasian ... plays a crucial role in determining the individual risk ... study was conducted by Dr. Geoff Ball and his ...
... Ramadoss said that India is crowned as the diabetic capital. ... national programme for prevention and control of cardiovascular disease, //stroke ... meeting. ,He submitted a draft of the programme ... to make it workable. ,The programme’s main ...
... global network of virus, spyware and spam analysis centers, have warned ... across the internet.// ,This letter claims that lipstick causes ... contain a dangerously high level of lead which can cause cancer. ... claims are not true. ,Sopho has asked the users ...
... incidence of pregnancy complications, more specifically preeclampsia related//, ... Obstetrics and Gynecology. ,Preeclampsia, a pregnancy-related ... (high levels of protein in the urine). Swelling ... seen. If left unattended, the condition can worsen ...
... the women especially the pregnant women about the risks ... as selective serotonin re-uptake inhibitors //(SSRIs) affect the fetus. ... called persistent pulmonary hypertension in babies born to women ... The recent study links SSRIs to this fatal condition ...
Cached Medicine News:Health News:African American Children More Pone to Develop Diabetes 2
BD Persist Plus protective barrier provides a one-step antimicrobial barrier with minimum of 1% chlorhexidine with Up to 7-day antimicrobial effectiveness....
The design of the new ChloraPrep swabstick applicator provides significant improvement in performance over traditional swabsticks....
... Swabsticks are packaged in easy open, single-use ... saturated with precisely the correct amount of ... the safest possible product for the patient. ... an excellent combination of ethyl alcohol and ...
... provides 5% povidone-iodine solution ... It delivers a microbicidal ... tender to touch. It ... indicated whenever effective microbicidal ...
Medicine Products: